Trials / Completed
CompletedNCT01579383
Safety Tolerability and Pharmacokinetics of ALD403
A Single Dose, Placebo-Controlled, Ascending Dose Study to Determine the Safety, Tolerability and Pharmacokinetics of ALD403, a Humanized Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody Administered by Intravenous Infusion and Subcutaneous Injection
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Alder Biopharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of ALD403, a monoclonal antibody, administered by intravenous infusion and subcutaneous injection.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ALD403 | Single Dose IV infusion on Day 1 |
| BIOLOGICAL | ALD403 | Single Dose subcutaneous injection on Day 1 |
| BIOLOGICAL | Sumatriptan | Single Dose subcutaneous injection on Day 1 |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2012-12-01
- Completion
- 2013-04-01
- First posted
- 2012-04-18
- Last updated
- 2013-04-26
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT01579383. Inclusion in this directory is not an endorsement.